In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Japanese drugmaker Takeda has put plenty on the line to acquire NDI-034858 from privately-held US drug discovery company Nimbus Therapeutics. 13 December 2022
Biotechnology
Shares in Moderna were up by nearly a quarter at lunchtime Tuesday. 13 December 2022
Biotechnology
The retiring Paul Perreault is to be replaced by another Paul as chief executive and managing director of Australian biotech CSL Limited. 13 December 2022
Pharmaceutical
Providing further evidence that generics major Viatris is pushing wider beyond copy drugs, the company has entered into an exclusive license agreement with Sweden’s Calliditas Therapeutics to register and commercialize the latter’s Nefecon in Japan. 13 December 2022
Biotechnology
Terms for a strategic collaboration in the area of cell and gene therapies have been agreed between Wave Life Sciences and GSK. 13 December 2022
Biosimilars
Biosimilar medicines deliver access for patients suffering from serious and debilitating conditions such as cancer, auto immune diseases, and diabetes. 13 December 2022
Biotechnology
Troubled US biotech Clovis Oncology has officially filed for bankruptcy in Delaware, hit by a fall in its cancer drug sales and challenges in raising additional capital, and will also seek to sell its assets through a court supervised sales process. 13 December 2022
Biotechnology
German immuno-oncology company Affimed has sought to impress with data on its blood cancer candidates at the ongoing ASH (American Society of Hematology) meeting. 13 December 2022
Biotechnology
US biotech major Regeneron added to its offering at this year’s American Society of Hematology (ASH) meeting with data on linvoseltamab in multiple myeloma. 13 December 2022
Pharmaceutical
Eli Lilly’s (NYSE: LLY) oncology company, Loxo@Lilly, has announced updated clinical data from the global Phase I/II BRUIN trial of pirtobrutinib. 13 December 2022
Biotechnology
A second KRAS blocker has won US approval, opening further a market in oncology based on a target that was once thought undruggable. 13 December 2022
Pharmaceutical
Indian pharmaceutical companies are on an acquisition spree after a decade of caution and organic growth. And their main target appears to be cancer drugs. As patient numbers continue to rise, the country's Parliamentary panel has also called for free cancer treatment to middle-class households through a government-funded health insurance scheme, reports The Pharma Letter’s India correspondent. 13 December 2022
Pharmaceutical
Belgium’s largest pharma company UCB yesterday announces that its board of directors has accepted the resignation of Stefan Oschmann as chairman and board member of the firm. 13 December 2022
Pharmaceutical
Drugmakers Novo Nordisk, Daiichi-Sankyo, Lundbeck, AstraZeneca, UCB and Biogen have been named and shamed by the UK pharma trade group. 12 December 2022
Biotechnology
USA-based Regeneron Pharmaceuticals has announced positive new and updated data from the Phase I ELM-1 and pivotal Phase II ELM-2 trials of its lymphoma candidate odronextamab. 12 December 2022
Pharmaceutical
At its December meeting today, the board of directors of Swiss pharma giant Roche approved to propose some major board changes at the Annual General Meeting, which will take place on March 14, 2023: 12 December 2022
Biotechnology
With Imbruvica (ibrutinib) sales of nearly $10 billion recorded by Janssen and AbbVie combined in 2021, the blood cancer drug has already changed the standard of care for patients in certain settings. 12 December 2022
Biotechnology
Coming as no surprise following rumors for the last couple of weeks, but with a much bigger price tag than had been expected, US biotech giant Amgen today announced that it is to acquire Horizon Therapeutics. 12 December 2022
Biotechnology
Autoimmune diseases specialist argenx has previously referred to Vyvgart (efgartigimod alfa-fcab), an antibody fragment that binds to the neonatal Fc receptor (FcRn), as a ‘pipeline in a product’. 12 December 2022
Biotechnology
Developed by the UK’s AstraZeneca (LSE: AZN) in collaboration with scientists at the University of Oxford, Vaxzevria (ChAdOx1-S [Recombinant]) was one of the first COVID-19 vaccines to come on the market, but it has been far less successful than the mega money-spinners such as Pfizer and BioNTech’s Comirnaty and Moderna’s Spikevax, not to mention that it has been sold at cost and has never been approved in the vast US market. 12 December 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze